Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
Company Details
- Employees
- 19
- Founded
- -
- Address
- One Kendall Square, Building 600/700,
- Phone
- +1 617 577 0300
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- evelobio.com
- HQ
- Cambridge, MA
Evelo Biosciences Questions
Evelo Biosciences's helpline number is +1 617 577 0300
Evelo Biosciences's website is evelobio.com
Evelo Biosciences's LinkedIn profile is https://www.linkedin.com/company/evelo-biosciences
Evelo Biosciences has
19 employees.
View email and phone details for 19
employees at Evelo Biosciences.
Evelo Biosciences's industry is
Biotechnology Research
Evelo Biosciences's top competitors are
Kaleido Biosciences,
Boston Bioprocess,
Finch Therapeutics,
Flagship Pioneering,
Seres Therapeutics,
Rubius Therapeutics,
Tessera Therapeutics,
Vedanta Biosciences, Inc.,
Intellia Therapeutics, Inc.,
Beam Therapeutics.
Evelo Biosciences's support email address is info@evelobio.com
Evelo Biosciences's categories are Biotechnology Research
Evelo Biosciences's founding year is 2015
